Bruce Hart
General Counsel at Zymeworks BC, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Ken Galbraith | M | 61 |
Zymeworks BC, Inc.
 Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | 16 years |
| Susan Mahony | M | 59 |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | 5 years |
| Hollings Renton | M | 77 |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | 7 years |
| Kelvin Neu | M | 50 |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | 4 years |
| Kenneth Hillan | M | 63 |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | 7 years |
| Jennifer Kaufman-Shaw | M | 74 |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | 10 years |
| Troy Cox | M | 60 |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | 5 years |
| Daniel Dex | M | - |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | 7 years |
| Christopher Astle | M | 45 |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | 3 years |
| Mark Hollywood | M | 55 |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | 5 years |
| Paul Moore | M | 58 |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | 2 years |
| Carlos Campoy | M | 60 |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | - |
| Jack Spinks | M | - |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | - |
| Kaycia Wilde | M | - |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | 3 years |
| Diana Papove | F | - |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | - |
| Derek Miller | M | - |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Ali Tehrani | M | 52 |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | 19 years |
| Nick Bedford | M | 64 |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | 16 years |
| Neil Klompas | M | 52 |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | 15 years |
| Ryan Dercho | M | - |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | - |
| Diana Hausman | M | 61 |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | 5 years |
| Kathryn O'Driscoll | F | 60 |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | 3 years |
| Anthony Polverino | M | 61 |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | 4 years |
| Neil Josephson | M | - |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | 4 years |
| Kavita V. Shah | M | - |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | - |
| James Daniel Guylain Priour | M | 57 |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | - |
| Mary Klem | F | - |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | 2 years |
| Guowei Fang | M | - |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Canada | 28 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Bruce Hart
- Personal Network
